Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kumorixilib + Capecitabine + Letrozole Neoadjuvant Therapy for HR+/HER2- Breast Cancer
NCT07691333Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of kumorixilib in breast cancer, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Percentage change in Ki-67 score at 4 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
kumorixilib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07691333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691333.